이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock (DISCO-SHOCK)

2026년 8월 15일 업데이트: tugba yesilyurt dogu, Istanbul University - Cerrahpasa

Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock: A Prospective Observational Cohort Study Evaluating Its Prevalence and Prognostic Value

In septic shock, restoring large-vessel (macrocirculatory) perfusion-reflected by a normal capillary refill time (CRT)-does not always mean that oxygen use at the tissue level has recovered. This mismatch, sometimes called loss of hemodynamic coherence, may be detectable by comparing CRT with the oxygen extraction ratio (O₂ER), a marker of how much oxygen the tissues are extracting from the blood. Patients whose CRT has normalized but whose O₂ER remains abnormal-either too high (suggesting oxygen delivery that is insufficient for demand) or too low (suggesting microcirculatory shunting)-are considered to have a "discordant" perfusion phenotype.

This prospective, single-center, observational cohort study aims to determine how often this CRT-O₂ER discordance occurs at the 6th hour of resuscitation in adult patients with septic shock, and whether it is associated with 28-day mortality. Approximately 100 consecutive adult patients diagnosed with septic shock (with pre-existing central venous and arterial catheters) will be followed. Clinical and laboratory measurements-including CRT, O₂ER, lactate, mottling score, and organ dysfunction scores-will be recorded at hours 0, 6, 12, and 24, with the main phenotype grouping performed at hour 6. The study is purely observational: CRT is a painless, non-invasive bedside measurement, and O₂ER is calculated from blood gas samples already drawn as part of routine care, so no additional interventions or blood draws are performed for research purposes.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Background. In septic shock resuscitation, improvement of macrocirculatory targets such as blood pressure and capillary refill time (CRT) does not always reflect adequate oxygen utilization at the tissue level-a phenomenon described as loss of hemodynamic coherence. Although the ANDROMEDA-SHOCK trial highlighted CRT-targeted resuscitation, a subset of patients with a normalized CRT may still have impaired tissue oxygen balance. The oxygen extraction ratio (O₂ER) can deviate in two directions: a high O₂ER (>30%) suggests oxygen delivery that is insufficient for demand (e.g., low cardiac output, anemia), whereas a low O₂ER (<20%, with high central venous oxygen saturation) may reflect microcirculatory shunting and cytopathic hypoxia.

Primary aim. To determine the prevalence of the "discordant" phenotype-defined as a normalized CRT with an abnormal O₂ER at hour 6 of resuscitation-and to evaluate its association with 28-day mortality.

Secondary aims. (1) To examine the association between CRT/O₂ER-defined perfusion phenotypes and 28-day mortality, ICU and hospital length of stay, duration of mechanical ventilation, vasopressor-free days, and need for renal replacement therapy; (2) to validate the proposed O₂ER >30% threshold using ROC curve analysis and identify the optimal cut-off for mortality in this cohort; (3) to assess whether the discordant phenotype is an independent predictor of mortality after adjustment for age, APACHE II score, lactate, and noradrenaline dose using multivariable analysis; (4) to examine the relationship of discordance with complementary perfusion markers (lactate clearance, mottling score, venoarterial CO₂ difference).

Design and setting. Prospective, single-center, observational cohort study in an intensive care unit. Consecutive adult patients diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline will be enrolled. Time zero (Hour 0) is defined as the time of vasopressor (noradrenaline) initiation.

Measurements. While patients continue standard care, serial clinical and laboratory measurements are recorded at hours 0, 6, 12, and 24, and organ function at hour 72. CRT is measured in a standardized manner on the ventral surface of the distal phalanx of the right index finger after 10 seconds of firm pressure. O₂ER is calculated as (SaO₂ - ScvO₂) / SaO₂. At hour 6, CRT and blood gas sampling are performed simultaneously (within 15 minutes). Inter-rater reliability of CRT is assessed in the first 20-30 patients by two independent, blinded observers (ICC for continuous values; Cohen's kappa for the ≤3 s normal/abnormal classification).

Phenotype grouping (Hour 6). Group 1 - Concordant normal (CRT ≤3 s + O₂ER 20-30%); Group 2a - Discordant, high O₂ER (CRT ≤3 s + O₂ER >30%); Group 2b - Discordant, low O₂ER (CRT ≤3 s + O₂ER <20%); Group 3 - Concordant abnormal (CRT >3 s + abnormal O₂ER). The primary group of interest is the combined discordant phenotype (Group 2a + Group 2b).

Outcomes. Primary outcome: 28-day mortality (counted from Hour 0). Secondary outcomes: ICU and hospital length of stay, duration of mechanical ventilation, time to vasopressor weaning, vasopressor-free days, hour-72 organ function (SOFA-2, ongoing vasopressor/ventilation, lactate), and need for renal replacement therapy.

Sample size and statistics. A target of approximately 100 consecutive patients was chosen so that an expected discordance prevalence of ~30% can be estimated with a 95% confidence interval half-width of ±9%. Descriptive statistics, normality testing (Shapiro-Wilk), and appropriate parametric/non-parametric group comparisons will be used. The prevalence of the discordant phenotype will be reported with 95% CI. ROC analysis (with AUC) will evaluate the O₂ER threshold for mortality. Multivariable binary logistic regression (parsimonious model: phenotype, APACHE II, lactate; events-per-variable ≈12) will identify independent predictors of mortality, reported as odds ratios with 95% CI. Survival across phenotype groups will be estimated by Kaplan-Meier analysis and compared with the log-rank test. Statistical significance is set at p < 0.05.

연구 유형

관찰

등록 (추정된)

100

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Tugba Yesilyurt Dogu, Intensive Medicine Care Fellow
  • 전화번호: +9005535150847
  • 이메일: tugbaayesilyurt@gmail.com

연구 장소

      • Istanbul, 터키 (Türkiye)
        • 모병
        • Başakşehir Çam and Sakura City Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

Consecutive adult patients (≥18 years) admitted to a single-center intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who already have a central venous catheter and an arterial line in place as part of their clinical care. Patients are enrolled from all admission sources (emergency department, ward, operating room, or external referral) and followed prospectively while receiving standard treatment. Patients with active bleeding, ongoing ECMO, conditions that make capillary refill time measurement unreliable (e.g., Raynaud phenomenon or significant peripheral vascular disease), death within the first 6 hours, or inability to obtain hour-6 CRT or blood gas measurements are not included.

설명

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline
  • Presence of both a central venous catheter and an arterial line

Exclusion Criteria:

  • Active bleeding
  • Ongoing extracorporeal membrane oxygenation (ECMO)
  • Raynaud phenomenon or significant peripheral vascular disease that makes capillary refill time measurement unreliable (e.g., critical ischemia, amputation, digital ulcer/necrosis, or inability to measure on the right index finger)
  • Death within the first 6 hours
  • Inability to obtain hour-6 CRT or blood gas (phenotyping not possible)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
septic schoc cohort
Consecutive adult patients (≥18 years) admitted to the intensive care unit and diagnosed with septic shock according to the Surviving Sepsis Campaign (SSC) 2026 guideline, who have pre-existing central venous and arterial catheters. Patients are prospectively followed while receiving standard care, with serial measurements at hours 0, 6, 12, and 24 (time zero = vasopressor initiation). At hour 6, patients are classified into perfusion phenotypes based on capillary refill time (CRT) and oxygen extraction ratio (O₂ER): concordant normal, discordant with high O₂ER, discordant with low O₂ER, and concordant abnormal. The primary group of interest is the combined discordant phenotype (normalized CRT with abnormal O₂ER).
Non-invasive, standardized bedside measurement of capillary refill time on the right index finger.
Oxygen extraction ratio calculated as (SaO₂ - ScvO₂)/SaO₂ from routinely obtained arterial and central venous blood gases.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Prevalence of the discordant CRT-O₂ER phenotype
기간: At hour 6 of resuscitation (6 hours after vasopressor initiation)
Proportion of patients classified as having a discordant perfusion phenotype (normalized CRT ≤3 s with an abnormal O₂ER, i.e., >30% or <20%; combined Group 2a + Group 2b) at hour 6, reported with 95% confidence interval.
At hour 6 of resuscitation (6 hours after vasopressor initiation)
28-day all-cause mortality
기간: 28 days from Hour 0 (vasopressor initiation)
All-cause mortality at 28 days, and its association with the hour-6 perfusion phenotype.
28 days from Hour 0 (vasopressor initiation)

2차 결과 측정

결과 측정
측정값 설명
기간
ICU length of stay
기간: Through study completion, up to 28 days
Duration of intensive care unit stay in days.
Through study completion, up to 28 days
Hospital length of stay
기간: Through study completion, up to 28 days
Duration of hospital stay in days.
Through study completion, up to 28 days
Duration of mechanical ventilation
기간: Through study completion, up to 28 days
Total days on mechanical ventilation (0 if never ventilated).
Through study completion, up to 28 days
Time to vasopressor weaning
기간: From Hour 0 up to 28 days
Time in hours to sustained vasopressor discontinuation (off ≥24 continuous hours), measured from Hour 0.
From Hour 0 up to 28 days
Vasopressor-free days
기간: 28 days
Number of days alive and free of vasopressor support within 28 days.
28 days
Organ dysfunction at hour 72
기간: Hour 72
SOFA-2 score at hour 72, together with ongoing vasopressor/mechanical ventilation status and lactate level.
Hour 72
Need for renal replacement therapy (RRT)
기간: Within 28 days
Proportion of patients requiring newly initiated RRT within 28 days (chronic dialysis patients excluded from the "new" category).
Within 28 days

기타 결과 측정

결과 측정
측정값 설명
기간
Diagnostic performance of the O₂ER threshold for mortality
기간: Hour 6 measurement; mortality at 28 days
Discriminative ability of O₂ER for 28-day mortality assessed by ROC analysis (area under the curve), with identification of the optimal cut-off and comparison to the literature threshold of 30%.
Hour 6 measurement; mortality at 28 days
Inter-rater reliability of CRT measurement
기간: Hour 6, first 20-30 patients
Agreement of hour-6 CRT between two independent, blinded observers; intraclass correlation coefficient (ICC) for continuous values and Cohen's kappa for the ≤3 s normal/abnormal classification.
Hour 6, first 20-30 patients

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 17일

기본 완료 (추정된)

2027년 6월 17일

연구 완료 (추정된)

2027년 7월 17일

연구 등록 날짜

최초 제출

2026년 8월 15일

QC 기준을 충족하는 최초 제출

2026년 8월 15일

처음 게시됨 (실제)

2026년 8월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 15일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • KAEK-11/29.07.2026.276 (기타 식별자: BASAKSEHİR CAM AND SAKURA CITY HOSPITAL)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .